Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic observational study I Kister, Y Patskovsky, R Curtin, J Pei, K Perdomo, Z Rimler, I Voloshyna, ... Annals of Neurology 91 (6), 782-795, 2022 | 22 | 2022 |
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies I Kister, R Curtin, J Pei, K Perdomo, TE Bacon, I Voloshyna, J Kim, ... Annals of Clinical and Translational Neurology 9 (10), 1643-1659, 2022 | 11 | 2022 |
Molecular mechanism of phosphopeptide neoantigen immunogenicity Y Patskovsky, A Natarajan, L Patskovska, S Nyovanie, B Joshi, B Morin, ... Nature communications 14 (1), 3763, 2023 | 9 | 2023 |
Longitudinal study of humoral and cellular responses to COVID-19 mRNA vaccines with and without 3rd (" booster") dose in MS patients on ocrelizumab: 24-week results from VIOLA … I Kister, A Piquet, R Curtin, A Yu, I Voloshyna, V Yogambigai, S Nyovanie, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 842-843, 2022 | 1 | 2022 |
Antibody and T-cell responses to SARS-CoV-2 vaccines in MS patients on Ocrelizumab and other disease-modifying therapies: preliminary results of an ongoing, prospective study I Kister, Y Patskovsky, I Voloshyna, N Ferstler, R Curtin, V Yogambigai, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 755-756, 2021 | 1 | 2021 |
Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination I Kister, R Curtin, AL Piquet, T Borko, J Pei, BL Banbury, TE Bacon, A Kim, ... Annals of Clinical and Translational Neurology, 2024 | | 2024 |
Structure of native four-repeat satellite III sequence with non-canonical base interactions E Chen, M Trajkovski, HK Lee, S Nyovanie, KN Martin, WL Dean, ... Nucleic Acids Research 52 (6), 3390-3405, 2024 | | 2024 |
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies (vol 10, pg1643, 2022) I Kister, R Curtin, J Pei, K Perdomo, TE Bacon, I Voloshyna, J Kim, ... ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2023 | | 2023 |
Humoral and Cellular Responses to SARS-CoV-2 Vaccines in MS Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Prospective Study From NYU Multiple Sclerosis Care … I Kister, Y Patskovsky, R Curtin, I Voloshyna, K Perdomo, Z Rimler, J Pei, ... Neurology 98 (18_supplement), 2697, 2022 | | 2022 |
Vaccine against SARS-CoV2-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA): study design and early results I Kister, A Piquet, Y Patskovsky, I Voloshyna, N Ferstler, R Curtin, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 795-796, 2021 | | 2021 |
Engineering T cells with improved TCR-CD3 interaction for optimal tumor killing V Yogambigai, A Natarajan, C Ge, Z Yuan, K Li, J Kim, HW Shin, ... The Journal of Immunology 206 (1_Supplement), 25.02-25.02, 2021 | | 2021 |
Biophysical studies of G-quadruplex DNA in complexes with small molecule ligands A Yett, S Nyovanie, L Yatsunyk ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 256, 2018 | | 2018 |
Synthesis of Organosiloxanes and Organoclays for Polymer-clay Nanocomposites ST Nyovanie Amherst College, 2017 | | 2017 |